Amphastar Pharmaceuticals (NasdaqGS:AMPH) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsBill Peters - CFODan Dischner - SVP of Corporate CommunicationsPavan Patel - Associate of Biotech & Pharma Equity ResearchSerge Belanger - Managing Director of BioPharma Equity ResearchTony Marrs - EVP of Regulatory Affairs and Clinical OperationsConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystEkaterina Knyazkova - Equity Research AnalystTianxi Cai - Ana ...

Emergent BioSolutions (NYSE:EBS) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsFrank Vargo - TreasurerJoe Papa - President and CEORich Lindahl - EVP and CFOOperatorPlease be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Frank Vargo, Treasurer. Please go ahead.Frank VargoGood afternoon, everyone. Thank you for joining today as Emergent discusses their operational and financial results for the fourth quart ...

Amphastar Pharmaceuticals (NasdaqGS:AMPH) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Speaker4Greetings, and welcome to the Amphastar Pharmaceuticals fourth quarter earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that certain statements made during this call regarding matters that a ...

■ 证券代码：600062 证券简称：华润双鹤 公告编号：临2026－012 华润双鹤药业股份有限公司 关于全资子公司西安京西双鹤药业 有限公司平衡盐冲洗液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司西安京西双鹤药业有限公司(以下简 称"京西双鹤")收到了国家药品监督管理局(以下简称"国家药监局")颁发的平衡盐冲洗液(以下简称"该药 品")《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要内容 二、药品相关情况 平衡盐冲洗液为无菌电解质水溶液，适用于外科冲洗。 京西双鹤于2022年1月启动该药品的仿制药研发工作，于2024年4月26日向国家药监局提交上市许可申 请，于2024年5月21日获得受理通知书，并于2026年2月10日获得国家药监局批准上市。根据国家相关政 策规定，本次获得《药品注册证书》视同通过一致性评价。 截至本公告日，公司针对该药品累计研发投入为人民币365.31万元(未经审计)。 三、同类药品的市场状况 平衡盐冲 ...

Syndax Pharmaceuticals (NasdaqGS:SNDX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsClara Dong - VP of Equity Research in BiotechnologyCorinne Johnson - Managing DirectorDavid Dai - DirectorJason Zemansky - VP of Equity ResearchJosh Bowen - DirectorKeith Goldan - CFOMichael Metzger - CEONick Botwood - Head of R&D and Chief Medical OfficerPriyanka Grover - VP of Biotechnology Equity ResearchSharon Klahre - Head of Investor RelationsStephen Willey - Managing DirectorSteve Closter - ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlan Krasner - Chief EndocrinologistCatherine Novack - Director of Healthcare Equity ResearchGayathri Diwakar - Head of Investor RelationsIsabel Kalofonos - Chief Commercial OfficerScott Struthers - Founder and CEOToby Schilke - CFOConference Call ParticipantsAlex Thompson - Senior Equity Research AnalystAndy Chen - Director and Senior Equity Research AnalystDennis Ding - VP and Equity Research ...

OPKO Health (NasdaqGS:OPK) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAdam Logal - SVP and CFOElias Zerhouni - Vice Chairman and PresidentGary Nabel - CIOPhillip Frost - Chairman and CEOYvonne Briggs - Director of Investor RelationsNone - Company RepresentativeConference Call ParticipantsBrian Cheng - Executive Director and Senior Biotech AnalystEdward Tenthoff - Managing Director and Senior Research AnalystMaury Raycroft - Equity Research AnalystYale Jen - Senior Biotech Analys ...

OPKO Health (NasdaqGS:OPK) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker5Hello and welcome to the OPKO Health Fourth Quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask your question, you may press Star then one on your telephone keypad. To withdraw your question, ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker14Welcome to Crinetics Pharmaceuticals' fourth quarter and full year 2025 financial results conference call. At this time, all participants are in listen only mode. Following management's prepared remarks, we will hold a question and answer session. In order to ask a question, please press star then 1 on your telephone. I'd now like to turn the call over to Gayathri Diwakar, Head of Investor Relations. Pleas ...

Syndax Pharmaceuticals (NasdaqGS:SNDX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker10Good day, everyone. Welcome to the Syndax fourth quarter 2025 earnings conference call. Today's call is being recorded. If you would like to ask a question following the company's prepared remarks, please press star five during the call. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.Speaker13Thank you, operator. Welcome, and thank you a ...